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Abstract
Objective—To estimate the association between over-the-counter nonsteroidal anti-inflammatory
drug (NSAID) exposure during the early first-trimester and risk for spontaneous abortion
(gestation prior to 20 weeks) in a prospective cohort.
Methods—Women were enrolled in the Right from the Start study (2004–2010). Exposure data
regarding over-the-counter NSAID use from the last menstrual period through the 6th week of
pregnancy were obtained from intake and first-trimester interviews. Pregnancy outcomes were
self-reported and verified by medical records. Gestational age was determined from last menstrual
period. Stage of development prior to loss was determined from study ultrasound. Cox
proportional hazards regression models were used to estimate the association between NSAID
exposure and pregnancy outcome, taking into account candidate confounders.
Results—Among 2,780 pregnancies, 367 women (13%) experienced an spontaneous abortion.
NSAID exposure was reported by 1,185 (43%) women. NSAID exposure was not associated with
spontaneous abortion risk in unadjusted models (hazard ratio [HR] = 1.01, 95% confidence
interval [CI] 0.82, 1.24) or models adjusted for maternal age (adjusted [aHR] = 1.00, 95% CI 0.81,
1.23).
Conclusions—Our findings suggest that use of non-prescription over-the-counter NSAIDs in
early pregnancy does not put women at increased risk of spontaneous abortion.
INTRODUCTION
In the United States each year, at least 1.5 million women use nonsteroidal anti-
inflammatory drugs (NSAIDs) around the time of conception, implantation, and early
embryonic development,(1–3) making them the most common medication exposure reported
in the first-trimester.(4) NSAIDs are primarily used to relieve pain and reduce inflammation
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and their effects generally result from inhibition of cyclooxygenase (COX)-2. Recently,
three population-based observational cohort studies have implicated first-trimester NSAID
use as a risk factor for spontaneous abortions (SAB or miscarriage) using data obtained from
pharmacy records or study interviews that limited NSAID exposure to a subset of NSAIDs
(e.g. ibuprofen, naproxen).(5–7) However, studies have not examined NSAID exposure and
risk for adverse pregnancy outcomes considering all forms of over-the-counter formulations
in early pregnancy.
Women and their care providers currently lack clear empirical evidence to inform clinical
care regarding the consequences of NSAID use during pregnancy. Prior evidence linking
NSAIDs to SAB risk is inconclusive due potentially to recall bias, limited power, and/or
incomplete documentation of NSAID exposure for all participants. This includes lack of
information about over-the-counter NSAID exposure that should more accurately represent
typical NSAID use during early pregnancy. We used data from the Right from the Start
(RFTS) study (2004–2010), a non-clinical, community-based pregnancy cohort, to examine
NSAID use during the early first-trimester of pregnancy as it relates to risk for SAB. This
study tests whether over-the-counter NSAIDs used early in the first-trimester are associated
with SAB risk.
MATERIALS AND METHODS
Study Population and Data Collection Protocol
RFTS is an ongoing community-based cohort that began enrolling in 2000. Over time, RFTS
has been funded in three major phases (RFTS1, 2, 3), and has enrolled participants in
Galveston, TX; Memphis, Nashville, Knoxville, and Chattanooga, TN; and the Research
Triangle region (Raleigh, Durham, and Chapel Hill) in NC. RFTS1 participants were
excluded from the analyses (n = 1,956) because over-the-counter NSAID use was not
ascertained during the interview. RFTS participants are 18 years or older and did not use
assisted reproductive technologies to conceive. Consent was obtained to review all records
pertaining to the study pregnancy. Direct marketing and recruitment strategies have been
described.(8)
Women who were not yet pregnant but trying to conceive could pre-enroll before pregnancy
and were followed until a positive pregnancy test. To avoid over-enrollment of sub-fertile
women, non-pregnant participants in the study had to be attempting to get pregnant for
fewer than six months (RFTS2) or fewer than three months (RFTS3). Women were eligible
for up to 12 months of pre-enrollment. Our RFTS study participant median gestational age at
enrollment since LMP was 42 days [interquartile range (IQR) 35 to 52 days]. Thirty-seven
percent of women were preenrolled in the study and enrolled upon confirmation of positive
pregnancy test. Participants completed an intake interview at enrollment and a computer
assisted telephone interview at the end of the first trimester. The computer assisted
telephone interview was conducted at a median gestational age since LMP of 98 days [IQR
95 to 103 days], providing information on history of bleeding or pain, medication use, and
exposure to potential confounders in the time since last menstrual period (LMP). Follow-up
was conducted to document outcomes. The institutional review boards (IRB) of Vanderbilt
University, Nashville, TN and the University of North Carolina, Chapel Hill, NC approved
this study.
Pregnancy outcomes were self-reported and abstraction of medical records was used to
verify outcomes. Live births were linked to state vital records to assist in verifying the
pregnancy outcomes for ongoing pregnancies. SABs were defined as a loss before 20
completed weeks’ gestation. Those without losses included both live births and stillbirths,
excluding ectopic pregnancies (n = 9) and induced abortions (n = 14). Gestational age was
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estimated from self-reported last menstrual period (LMP). We have previously shown that
the overall accuracy self-reported LMP in our cohort.(9) Women could enroll in RFTS
during more than one pregnancy, but only the first enrollment was included (n = 251
subsequent pregnancies excluded). RFTS also includes information on prescription
medications, including NSAIDs, in the first-trimester interview regarding prescription
medications taken for pain, bleeding, and other reasons. However, number of women
reporting prescription NSAID use was too small to perform statistical analyses (n = 10). We,
therefore, excluded prescription NSAIDs from the analysis.
NSAID Assessment and Other Variables
Participants were queried about all medications in the intake and first-trimester interviews
(Table 1). Both interviews included NSAID exposures during the periconceptional period,
(e.g. from LMP through 6 weeks gestation). The primary exposure was classified as any
NSAID use versus no NSAID use) based on whether the participant reported NSAID use in
either interview. NSAIDs were further grouped by drug class, generic name, and brand
name. The primary resource used to classify drugs was the Food and Drug Administration
drug classification database.(10) Other resources also utilized include: Micromedex 2.0,
Lexi-Comp ONLINE, Epocrates Online Premium, and DailyMed.(11–14) Over-the-counter
drugs not reported according to store brands and that could not be classified with the
previously listed resources were identified with drugstore.com.(15) We did not include
acetaminophen use in the NSAID definition, with the exception of drugs that included
acetaminophen and an NSAID as the active ingredients.
Maternal characteristics and obstetric history were also recorded. These included: maternal
age, height, weight, body mass index (BMI), race/ethnicity, diabetes status, parity, gravidity,
induced abortion history, study site, and smoking status (current or not current smokers).
Information on these characteristics was obtained from either the first-trimester interview or
in person during the study ultrasound visits.
Statistical Analysis
Analyses were conducted with STATA statistical software version 11.0 (StataCorp LP,
College Station, TX, USA). We used Cox proportional hazards survival models with
variable gestational age at study entry to characterize the rate of pregnancy loss in relation to
NSAID exposure (any versus none) both unadjusted and adjusted for confounders. Allowing
for variability for study participant gestational age at study entry will correctly estimate the
risk of SAB conditional on the fact that each subject had not had pregnancy loss before they
were recruited into the cohort.(16) Longitudinal data from each woman starts at enrollment
or after women report a positive pregnancy test if they pre-enrolled in the study and
continues through 20 completed weeks’ gestation, the occurrence of a pregnancy loss, or
loss to follow-up. We used a two-sided alpha=0.05 significance level for all tests of
statistical significance.
Candidate confounders included maternal age (years), BMI (kg/m2), race/ethnicity
(Caucasian [referent], African American, Hispanic ethnicity), income (≤ $40,000, $40,000–
$80,000 [referent], > $80,000), diabetes status (no diabetes [referent] versus any [type 1,
type 2, gestational, or multiple]), parity (none [referent] versus ≥ 1), gravidity (none
[referent] versus ≥ 1), induced abortion history (none [referent], ≥ 1), study site (North
Carolina [referent], Tennessee, Texas), and smoking status (not current [referent] versus
current). Candidate confounders were analyzed for independent association with both
NSAID exposure and SAB outcome. Those that were independently associated with NSAID
exposure and SAB outcome and that resulted in a 5% relative change in NSAID effect size
estimates were retained in the model. No candidate met inclusion criteria. However,
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analyses adjusted for maternal age are also presented because this covariate was commonly
included in multivariable models in previous studies of NSAID use and SAB risk.(5–7)
Using Cox regression, we estimated adjusted hazard ratios (HR) with 95 percent confidence
intervals (CI) for risk of miscarriage with NSAID exposure. Sub-analyses were performed to
assess whether the effect sizes varied by gestational age at time of SAB (gestation < 10
weeks vs. ≥ 10 weeks), and NSAID class. Additional secondary analyses were performed
examining the relationship between total days of NSAID use and SAB risk using Cox
regression. Total days of NSAID use was calculated based on the total number of days
reported across all NSAIDs an individual reported taking. Since individuals were asked the
same set of questions in the intake and first trimester interviews, we analyzed using the
largest number of days reported across the two sets of interviews. In order to compare our
findings with those from studies that have used different definitions for NSAID exposure we
also performed Cox regression analyses excluding aspirin from the NSAID exposure
definition.
Finally, we examined developmental stage at ultrasound among women who had a loss in
order to assess whether ultrasound characteristics differed if they were exposed versus
unexposed to NSAIDs. Ultrasound characteristics examined included: the presence of fetal
pole with a normal heart rate, fetal pole with an abnormal or no heart rate or an abnormal
heart rate, the presence of a gestational sac or the presence of a gestational sac and yolk sac,
an empty uterus with a positive pregnancy test.
RESULTS
We included a total of 2,780 women who enrolled in the study between 2004 and 2010
(Table 2). The overall prevalence of early first-trimester NSAID use among women in RFTS
was 43% (n = 1,185). In the total sample, 367 had an SAB (13%). Half of the losses
occurred prior to the 10th week of pregnancy. Compared to non-users, NSAID users were
more likely to be Caucasian, have had no previous pregnancies, and have had no history of
SAB. In bivariate analyses, increased maternal age, gravidity ≥ 1, African American race,
having an income greater than $80,000, and having a history of SAB were associated with
an increased risk of SAB (p < 0.05)). The most common class of NSAIDs taken were
propionic acids (n = 1,020, such as ibuprofen and naproxen) with similar use among NSAID
users with (83%) and without (86%) a loss (Table 3). Women also reported taking
salicylates (n = 293, primarily aspirin), acetic acids (n = 3, such as indomethacin), and
enolic acid derivatives (n = 1, piroxicam).
The unadjusted and adjusted models did not show an association between NSAID exposure
and SAB risk (unadjusted HR = 1.01, 95% CI 0.82, 1.24; adjusted [aHR] = 1.00, 95% CI
0.81, 1.23) (Table 4). Analyses stratified by early and late losses showed no association
between NSAID use and risk for early or late losses. We also examined SAB risk excluding
salicylates and did not observe an association (HR = 0.91, 95% CI 0.72, 1.15; aHR = 0.91,
95% CI 0.72, 1.14). Additional analyses of total days of NSAID use and SAB risk did not
show evidence of an association (Table 4).
We further examined whether risk for SAB by NSAID use differed by whether the interview
when NSAID data were collected was conducted prior to or after the loss occurred. All
women who had interviews after their loss (n = 42) reported NSAID use. When information
from ultrasound is incorporated to assess stage of pregnancy development prior to loss we
observed no difference in stage of arrested development among losses across the spectrum
from anembryonic gestation through normally developing early gestations (Table 5). A
summary of the probability of loss by gestational age and NSAID exposure is in Figure 1.
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Given the plausibility of NSAID effects on PG synthesis, embryo transport, implantation,
placental development, maintenance of pregnancy, and prior evidence from epidemiologic
data, we examined the relationship between periconceptional over-the-counter NSAID
exposure and SAB risk in a non-clinical cohort. We found no evidence of an association
between NSAID use and increased risk for SAB. Analyses stratified by NSAID class
suggested that aspirin users (salicylates) were possibly at increased risk of SAB; however,
this association was not statistically significant. In order to compare our results to those from
other studies that examined only the effect of only non-aspirin NSAIDs, we also performed
sub-analyses excluding aspirin users and did not observe and increased risk for SAB.(7)
However, we had less power to detect an association with aspirin use in our cohort relative
to prior studies of aspirin use and SAB risk. (7) Also, we note that a small subset of women
(n = 42) were interviewed after their SAB reported. All 42 women reported taking an
NSAID, which may indicate an element of recall bias but would be expected to bias results
towards an finding an association.
The biological basis for suspecting a link between NSAIDs and risk of SAB rests on the
multiple stages in development that involve prostaglandin (PG) synthesis, particularly
during early pregnancy when PGs, such as PG E synthases (PGES), may be essential for
establishing the implantation and early placentation, but may be protective later. NSAIDs
inhibit COX enzymes, which catalyze the formation of PGs from arachidonic acid and thus
reduce PG synthesis. PGs have important roles in both maintaining and achieving
pregnancy. For example, COX-2 knockout mice (that lack COX-2) ovulate fewer oocytes
have incomplete decidualization, have low fertilization rates, and fail implantation—all of
which can be improved by administering PGs.(17) Altering PG levels has direct effects on
conception, implantation, and maintenance of pregnancy in animal models.(18–28) Because
NSAIDs inhibit PG synthesis they may influence embryo transport, implantation, placental
development, and maintenance of pregnancy and have been shown to lead to embryonic
demise in animal models.(29) This suggests that NSAID use during early pregnancy is a
plausible biological candidate for causing a SAB.
Few studies have examined NSAID exposure and risk for SAB (Table 6). Two studies
examined prescription NSAIDs only. These include a Danish study that observed an
increased risk of SAB for women taking NSAIDs.(6) This study, using national healthcare
and pharmacy records, considered the effect of prescription NSAID use from 30 days prior
to conception through the end of pregnancy on risk of congenital anomalies, low birth
weight, preterm birth, and SAB in primagravid women. One percent of the cohort had been
prescribed NSAIDs. They observed a statistically significant association between NSAID
use and SAB for NSAIDs taken one week and up to nine weeks before the loss.(6) However,
in subsequent reexamination of results adjusting for gestational age (30) the association was
no longer statistically significant (NSAIDs taken one week and up to nine weeks before
SAB, OR 1.5–3.4, 95% CI 0.6–12.8). A second more recent study of prescription NSAIDs
conducted using the Quebec Pregnancy Registry observed that non-aspirin NSAID use was
associated with an increased risk of SAB with an OR = 2.4, (95% CI 2.1, 2.8) using NSAID
prescription data available in the registry for which both indication and duration of use are
likely to differ from over-the-counter. Three percent of their cohort reported exposure to
non-aspirin prescription NSAIDs.(7)
Only one prior study included non-prescription NSAIDs, and their analysis included
adjustment for gestational age at entry. (5) This study used self-reported NSAID use,
including prescription and over-the-counter NSAIDs (ibuprofen, naproxen, Advil, Motrin,
and Naprosyn), with a cohort of patients from Kaiser Permanente HMO in northern
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California.(5) NSAID exposure included use between LMP and positive pregnancy test. The
authors reported that NSAID use around the time of conception resulted in a 5.6 increase in
hazard of SAB compared to no NSAID use (95% CI 2.3, 13.7). Five percent (n = 53) of the
cohort reported using NSAIDs during this gestational period.
In our study we collected data on all over-the-counter pain medications including
medications to prevent menstrual cramps in anticipation of menses, as well as medicine for
headaches, aches, pains, and colds. We then identified all specific classes of NSAIDs in
these medications. We used Cox regression and accounted for gestational age at enrollment
to accurately model time at risk.(5) However, we observed much higher use of NSAIDs
compared to what was reported by other studies (43%). Over-the-counter NSAIDs may be
more likely to be taken at low and intermediate dosages compared to prescribed forms of
NSAIDs, which may explain why the studies of prescription NSAIDs observed an increased
risk for SAB while we observed a null effect. There may also be other indications for
NSAID use among women who take prescribed NSAIDs (e.g., a chronic medical condition)
that put them at increased risk of SAB.
We observed a much higher exposure rate of NSAIDs in our cohort than was previously
observed 5% for the Li and colleagues study (2003), which also attempted to captured both
prescription and non-prescription NSAID exposures.(5) This is likely due to differences in
exposure assessment. We asked about any type of pain or cold medication and then
determined whether it included NSAIDs while Li and colleagues (2003) limited NSAIDs to
a specific subset. As a result, Li and colleagues (2003) may have missed some women
exposed to NSAIDs. Another difference is the timing of the interviews across our studies. Li
et al. (2003) interviewed participants immediately after pregnancy confirmation, capturing
exposures between LMP and pregnancy confirmation. While in our study we obtained data
from baseline screening interviews after pregnancy confirmation and from first-trimester
interviews targeted at less than 13 weeks that specifically ask about use between LMP and
six weeks. Finally, it may be the case that prescription NSAID use was responsible for the
observed association with SAB in the previous studies. Because exposure to prescription
NSAIDs was rare in our study population, we excluded the 10 women who were known to
have been exposed to prescription NSAIDs.
We did not observe an association between NSAIDs and SAB risk; however, our findings
have implications for women taking over-the-counter NSAID during pregnancy. In our
cohort, assuming an alpha of 0.05 and a 13% prevalence of SABs we would have 81%
power to detect an HR of 1.35, which is well below the risk estimate observed in prior
studies. We show that typical over-the-counter NSAIDs taken by women during the first-
trimester of pregnancy do not put them at increased risk of SAB. Due to limited numbers,
we could not directly address the previous findings that focused on prescription-based
NSAIDs, which are more likely to be at higher dosages and reflect a different risk due to
NSAID exposure than what we observed in our study. It is also possible that women did not
indicate if they took a prescribed NSAID or that they did not distinguish between prescribed
and unprescribed forms. Our rate of miscarriage, 13%, is consistent with most
epidemiological studies that are looking at SAB in the context of clinical recognized
pregnancies. Further research is necessary to assess whether NSAID exposure prior to
implantation or shortly after may cause an SAB prior to clinical recognition of pregnancy.
Finally, further understanding the role of dose, timing in gestation, and the potential role of
recall bias may help to reconcile this with previously observed associations between
NSAIDs and SAB.
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Figure 1. Cumulative probability of SAB when exposed to NSAIDs
Figure 1 shows the probability of miscarriage by NSAID exposure. Gestational age in weeks
is provided on the X-axis and the Y-axis indicates the cumulative probability of a SAB.
Those unexposed to NSAIDs are labeled with a circle and those exposed to NSAIDs are
labeled with a diamond.
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